Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 1s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Assess the effect of clinical pharmacy services on pediatric patient outcomes, including hospital readmissions and quality of life

Pranjul Shrivastava[1], Syed Sajid Ali Syed Sabir Ali[2]

[1]Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.
[2]Research Scholar, Department of Pharmacy, Kalinga University, Raipur, India.

Cite this paper as: Pranjul Shrivastava, Syed Sajid Ali Syed Sabir Ali, (2025) Assess the effect of clinical pharmacy services on pediatric patient outcomes, including hospital readmissions and quality of life. *Journal of Neonatal Surgery*, 14 (1s), 110-117.

ABSTRACT

It has been demonstrated that clinical pharmacy services enhance patient outcomes across a range of demographics. It is unknown, therefore, how these services affect the results of pediatric patients. to evaluate how clinical pharmacy services affect pediatric patients' quality of life and hospital readmissions. Clinical pharmacy services can enhance quality of life and decrease readmissions to hospitals for pediatric patients. The inclusion of clinical pharmacy services in pediatric care is supported by these findings. The current dissertation focuses on the quality of prescribing practices and the monitoring of medication safety, specifically the surveillance of these practices once regulatory bodies have determined that the drugs' efficacy, quality, and safety are sufficiently established for their use in clinical practice. The thalidomide tragedy in the early 1960s raised awareness of the dangers of medicines. In addition to strict approval processes, a plan was created to keep an eye on the safety of marketed medications because of the significant increase in risk. Pharmacovigilance is in charge of the scheme's theoretical foundation as well as its actual execution. The primary foundation of an implementation pharmacovigilance approach is a (spontaneous) reporting system that allows medical practitioners to report any suspicions of adverse drug reactions (ADRs), which are then investigated. This thesis examines the quality of prescribing practices and pharmacovigilance, including what they involve and how they might be enhanced.

Keywords: *Adverse drug reactions, pediatrics, quality of life.*

1. INTRODUCTION

For millennia, adverse drug reactions (ADRs) have been recognized as a major source of morbidity and mortality. ADRs raise mortality, lengthen hospital stays, increase hospitalizations, and substantially lower quality of life. ADRs also have a huge financial impact on health care systems. Prescribers, pharmacists, nurses, regulatory bodies, the pharmaceutical industry, and the general public all place a high priority on the safe use of medications. No medication is given without risk, even if prescribers try to use ones that benefit patients and do no damage. Patients, who are becoming more conscious of the issues related to medication therapy, owe healthcare providers a duty. Healthcare workers' awareness of the negative effects of medications is becoming more and more crucial. Understanding the frequency, severity, predictability, and reversibility of adverse drug reactions is essential to efficiently minimizing their occurrence.

Monitoring is the process of examining a system that evolves over time in order to direct modifications that will preserve or enhance it. The three elements of monitoring are analysis, action, and proactive, focused observations. The broader issue of tracking the health of people with chronic illnesses has been brought to light by medical monitoring (Glasziou P. 2005). In order to prevent or lessen the harm caused by adverse medication reactions, monitoring is frequently recommended. There is frequently a trade-off between the seriousness of the response, which makes it more valuable to find each case, and the rarity of the adverse reactions, which lowers the value of monitoring 1. by making detection rare and 2. by raising the number of false-positive results. One way to practice active pharmacovigilance is through drug event monitoring. To guarantee comprehensive and accurate data on adverse events, active surveillance can be accomplished by looking at medical records or by speaking with patients and/or doctors. One of the approaches used to gather information on medication prescriptions and adverse events is hospital-based adverse event monitoring. With this approach, skilled medical professionals keep an eye on patients who are admitted to a particular hospital by going over their medical records and interviewing patients and doctors in a systematic manner. The case record form can contain details about the patient's demographics, indication for the treatment, length of therapy (including start dates), dosage, clinical events, and reasons for stopping the treatment (Schumock

et al., 1992, Coulter DM, 2000). Since there is an inherent risk associated with all medical products, adverse drug responses and adverse drug events are a prevalent clinical concern, particularly in hospitals. In India, adverse event monitoring has been carried out through an extensive event monitoring program, in which pharmacovigilance officers gather adverse event data from hospital departments. He must discuss the adverse incident with the corresponding unit's physician. Numerous shortcomings exist in the system for reporting adverse events, including the fear of personal and organizational liability, time-consuming, labor-intensive, and complex reporting procedures, the lack of incentives, rewards, or motivation to report, and the lack of feedback given to reporters. However, a high percentage of underreporting, which varies according on the kinds of ADRs and medications in question, is a characteristic of these systems. Reporting rates have been demonstrated to be impacted by educational interventions. To date, no research has been conducted that focuses on enhancing the ADRs' intensive event monitoring. The study's goal was to encourage medical professionals to report adverse events more frequently and accurately. In order to rule out the underreporting causes in the intensive event monitoring and interventional improvement in the same, the current study was designed.

2. THE ISSUES WITH DRUG SAFETY MONITORING

In India, pharmacovigilance is still very new, and little is known about the field (Biswas and Biswas, 2007). 2. ADR information is frequently inadequate and confidential. The precise incidence (either population- or prescription-based) of particular adverse drug reactions (ADRs) is unknown due to a lack of research on ADRs. The general public typically does not have access to information on adverse drug reactions (ADRs) from the pharmaceutical industry and regulatory bodies. (The 2005 Berlin Declaration) 3. Health professionals are frequently underreported, have little desire for pharmacovigilance, and receive little encouragement to participate in the process (Berlin Declaration, 2005). 4. Patients are given insufficient and difficult-to-understand information regarding ADRs. Professionals in reputable monitoring centers and regulatory bodies frequently reject patient reports, even though they are the only ones who truly experience the adverse drug reactions (ADRs) (Berlin Declaration, 2005). 5. In addition to having inadequate procedures for identifying ADRs, it is not customary to thoroughly investigate the root cause of issues when they do occur. Aviation accidents are thoroughly researched, the lessons learned are widely shared, and regulatory bodies make significant and costly adjustments mandatory. On the other hand, regulatory bodies do not consistently look into the reason and potential errors that may have caused the occurrences, even after hundreds of deaths have resulted in a drug being taken off the market (Berlin Declaration, 2005). 6. Due to the introduction of numerous powerful hazardous compounds as medications in the past two or three decades, the identification of adverse drug reactions (ADRs) in the intensive care unit has grown in importance.

2.1 Improvements in Drug Safety Are Needed

The safe, efficient, and confident use of medications depends on a functioning pharmacovigilance system. Furthermore, a system like this is advantageous to everyone involved, including the public, health professionals, insurance companies, regulators, and those who create health policy. Additionally, it helps the pharmaceutical industry avoid lawsuits, which can be expensive both financially and in terms of reputation. Despite this, companies have historically shown little enthusiasm because they believe that information about adverse drug reactions (ADRs) can hinder drug promotion, reduce sales, and ultimately lower shareholder profit.

When a product is first put on the market, there isn't much clinical practice experience with its safety and effectiveness; what is known comes from clinical trials that have mostly concentrated on proving efficacy, lasted a short while, and were conducted in hospitals or other closely watched environments. A study of pharmacovigilance protocols is especially pertinent at this time since, although pharmacovigilance should contribute to a better understanding of safety, several factors work together to thwart such arrangements in practice (Berlin Declaration, 2006). 2. The potential number of ADR victims will increase with the number of consumers of a recently introduced medication. ADRs that were not identified in clinical trials have the potential to impact thousands of patients before effective measures to reduce harm can be implemented in a time when the introduction of a new product can be supranational (for instance, launched simultaneously throughout the EU and frequently at the same time in other regions) and is accompanied by aggressive marketing. There is no comparable worldwide ADR monitoring system to the globalization of marketing.

Prescription-exclusively Medicines (POMs), which are currently exclusively available with a prescription, are being made available to the general public over-the-counter (OTC). Traditional pharmacovigilance arrangements are weakened by this change since prescribers avoid reporting adverse drug reactions (ADRs), clinicians are no longer involved, there are no organized methods for the public to report, and in many countries, pharmacists are not involved (Berlin Declaration, 2006). 4. Reports from customers: Since no medication is completely free of side effects, there is always some risk associated with using it. The most crucial factor in the creation and marketing of medications is managing risk. Customers have extensive firsthand knowledge from using the medications. A better word would be "patient reporting," which would relate to patients more than the pharmaceutical industry (International Society of Drug Bulletins (ISDB), 2001). There is still a lack of customer experience because only a few nations have released the findings of these investigations, which brings us to one of the dissertation's goals. 5. Official approval and quality control mechanisms, as well as pharmacovigilance systems, are largely circumvented by complementary medications. Since traditional medications are frequently used without the usual

labeling and packaging regulations, it could be challenging to determine what caused an adverse drug reaction (ADR) if the product's active ingredient is unclear from the package. Furthermore, if people think a treatment is risk-free and natural, they might not consider an incident to be a side effect of the product (and therefore not supervised worth alerting a health expert).

As community- or home-based therapy replaces hospital-based medical treatment, patients are becoming more involved in their own therapy. As a result, patients are now self-administering high-risk medications at home, such as heparins or cytotoxic medicines, which were previously only utilized in hospital settings. The quality, number, and perceived severity of the ADRs observed may vary as a result of this adjustment. Furthermore, as was previously said, pharmacovigilance and reporting procedures are not made to address observations made by patients. The project's overarching goal is to evaluate and create the most effective approach for drug safety monitoring and usage in drug surveillance, as well as to evaluate prescription quality and apply the 90% drug use idea. The work focuses on the pharmacovigilance process that works best for public health protection. By helping organizations create and maintain suitable and efficient pharmacovigilance systems, the information presented in this thesis is expected to support our goals of protecting, promoting, and improving public health. Research questions for evaluating how clinical pharmacy services affect the outcomes of pediatric patients:

2.2 Primary Research Questions

- How do clinical pharmacy services affect pediatric patients' readmission rates to hospitals?
- According to validated instruments, do clinical pharmacy services enhance pediatric patients' quality of life (QoL)?

2.3 Secondary Research Questions

- Which medication-related issues are most frequently noted by clinical pharmacists in pediatric patients?
- What is the impact of clinical pharmacy services on pediatric patients' persistence and adherence to medication?
- How cost-effective are clinical pharmacy services in lowering readmissions to hospitals and enhancing pediatric patients' quality of life?
- How do clinical pharmacy services affect the happiness of pediatric patients and caregivers?

2.4 Exploratory Research Questions

- Do certain pediatric groups—such as those with long-term illnesses—benefit more from clinical pharmacy services than others?
- What are the main elements of clinical pharmacy services that help pediatric patients achieve better results?

2.5 Specific objectives were to:

- To carry out the intense event monitoring interventional improvement in the ADR Monitoring Method
- To compare the characteristics of adverse drug reactions (ADRs) reported by consumers and health care professionals.
- To identify adverse drug reactions based on the method's utility and laboratory value for ADR detection
- To assess a trustworthy technique for detecting ADRs in the intensive care unit

3. METHODOLOGY

Only randomized controlled trials contrasting cefepime with other clinically recommended antibiotics were allowed to be included in this review. Due to the general lack of research in pediatric trials in the field of interest, open-label studies were allowed. The review did not include any observational or non-randomized studies. Author (Parthasarathy, 2024). The review was organized using the PICOTS methodology, which stands for Population, Intervention, Comparator, Outcome, Timing, and Setting. Children ages 0 to 19 who had fever, an increased white blood cell count, or other clinical indications of infection were included in our study sample (P). Intravenous (IV) or intramuscular (IM) cefepime was the evaluated intervention (I). Using standard pediatric dosages (50 mg/kg every 12 hours to 2 g every 8 hours, with a daily maximum of 6 g), it was given for 10–14 days. Comparators (C) included IV or IM beta lactams other than cefepime, carbapenem, aminoglycoside, or a "clinically indicated" antibiotic treatment. (Seidgar, 2024) We also looked at studies that compared cefepime to either no medication or a placebo. The study's main outcome was 30-day all-cause mortality, which is defined as being alive or dead 30 days after beginning cefepime medication (O). Mortality at the end of the research period was utilized as reported in cases where the 30-day all-cause mortality was not specified explicitly. (Sharma, R., 2024)The dichotomous result was the overall number of deaths per trial arm. (Koohpaei , A. 2015)The following were other noteworthy secondary outcomes: The incidence of adverse events, including antibiotic-associated morbidity—an irreversible adverse effect linked to antibiotics, such as hepatotoxicity, nephrotoxicity, or neurotoxicity—is the third factor.Author (Khyade , V. B ,2018). The first is the success rate, which is the resolution of fever with improvement of clinical symptoms without signs of infection; the second is treatment failure, which is the presence of a persistent infection following the completion of the entire course of treatment or the addition of a second agent covering the same spectrum. Timing (T): Results were monitored for a maximum of 30 days following the end of treatment, or, if that period was less, until the end of the index hospital stay. The follow-up period

was determined by individual studies, or if not specified, it concluded at the end of the study. Setting (S): Only antibiotics administered in inpatient hospitals were included in the trial.

3.1 Study Population

Participants in the study were inpatients aged 0–19 years with either a confirmed infection (culture data documented for infection), a suspicion of infection (low blood pressure, fever, elevated white blood cell count, elevated heart rate or respiratory rate, or patients undergoing chemotherapy at high risk for infection with minimal symptoms). The type of infection (pulmonary, cutaneous, soft tissue, urinary, etc.) was not restricted as long as the research team found cefepime to be clinically appropriate. Our sample consisted of patients with "fever of unknown origin" who were being treated empirically prior to the identification of an infectious etiology. There were no limitations on the number of participants, co-morbidity, gender, or ethnicity. We limited our participants to individuals under the age of 19. We included studies with participants older than our maximum age of inclusion if we could extract unique data for our target group. Patients were enrolled if they satisfied the selection requirements. The criteria for inclusion and exclusion vary from study to study.

3.2 Interventions

Studies contrasting typical pediatric cefepime dosages with controls were considered. Any additional IV or IM antibiotics that the authors determined were clinically indicated depending on the underlying illness process were included as controls. Author (Padmamma, S. 2019) Cefepime is best suited for individuals receiving empirical treatment for "fever of unknown origin," hence we also considered studies that compare it to a placebo or to no treatment at all. Only intravenous (IV/IM) delivery was used for the intervention; oral and other delivery techniques (such as peritoneal) were excluded. Included were studies that used any standard pediatric dosage and therapy duration (50 mg/kg every 12 hours to 2 g/every 8 hours, with a maximum dose of 6 g/day); the duration varied based on the course of the disease and ranged from around 10 to 14 days. The complex method of the investigation was explained at each stage.

3.3 General Procedure

The patient received a thorough explanation of the study's methodology prior to their enrollment. 3. Following a thorough explanation of the study and the resolution of any concerns, the patient or a family member provided written informed permission (ICMR Guidelines). 4. Details regarding the patient's financial situation were acquired. 5. A standardized proforma was used to record the information from the patients' prescription cards.

instruments Used: To enhance the medication safety monitoring techniques, new instruments were evaluated and put to use. Following the study's conclusion, data on a total of 3000 patients became accessible. The statistical analysis was conducted in accordance with the research. Details are provided in the study that was carried out.

3.4 Analysis of the study

One crucial indicator of prescription analysis is the average number of medications prescribed. Since higher numbers always result in a higher risk of drug interactions and higher hospital expenses, it is recommended to keep the mean number of medications per prescription as low as possible (Gupta N, 1997). According to the current study, only two medications—Ibuprofen (55.86%) and Voveran (29.29%)—have a 90% drug consumption rate among the orthopaedic population in the tertiary health care center. Both medications are classified as "high-risk" NSAIDs in the current study.



Figure 1: Pediatric patient's gender

We did not receive a prescription for the COX-2 inhibitor during this trial. The percentage of drug use in the IPD and OPD varies as well. According to the study, OPD patients use NSAIDs more frequently than IPD patients. (Joshi,2024). It has been discovered that oral medication is more effective than injectable NSAIDS. The outcome surprised me much because these are the safest medications that the government has approved. There is evidence that more complicated options may result in lower-quality prescriptions in markets with a large number of medications.



Figure 2: age of patients

Although the patients' drug expenditures were not determined to be particularly large, this expense could not be considered in a vacuum. The entire burden was increased by other expenses including travel costs and the time and money needed to seek out other providers. The growing financial strain on caregivers is mostly due to indirect expenses as well as direct ones. Orthopaedic IPD patients require lengthy treatment, which significantly raises treatment costs. The calcium supplement was provided for a longer period of time in addition to the NSAIDs.



Figure 3: Potential issues that may arise when assessing how clinical pharmacy services affect the outcomes of pediatric patients

All medications (100%) in this study were filled according to prescriptions. Every medication that Civil Hospital supplied and every medication that was prescribed from outside sources had labels. Eighty-eight percent of the medications used are from the WHO Essential Drug List (2007). (Santos Alcantara, 2023) ICU patients are medical emergencies who require immediate therapeutic interventions; however, the amount of medications must be kept to a minimum. in order to reduce medication interactions, side effects, and improve patient cost-effectiveness.



Figure 4: Issues in evaluating the impact of clinical pharmacy services on the outcomes of pediatric patients

In contrast to drug safety monitoring, the approach used in this dissertation can be helpful for the early detection, evaluation, comprehension, and prevention of adverse drug responses. With the new idea of Drug Utilization 90% on the Indian subcontinent, prescription quality will also be improved.



Figure 5: hospital readmissions



Figure 6: Quality of life for patients

4. DISCUSSION

This study outlines the most popular and effective method for measuring adverse drug reactions (ADRs) among hospital inpatients. In order to prevent patient damage in real-time and to support system-wide surveillance that may result in process improvement, trigger development aims to efficiently and effectively detect adverse events (AEs) (Resar RK et al., 2003). In order to identify ADEs, we used a trigger tool to analyze data in over 2800 records from four hospital departments with over 22,000 distinct medication doses. We discovered that the trigger tool may be effectively and reliably used to characterize the breadth and depth of the ADEs found in various inpatient organizations by using teams of two medical professionals. We combined voluntary and verbally requested reports from house officers and nurses with laboratory data from all hospitalized patients in the pediatric, dermatology, pathology, and medicine departments, as well as medication order sheets, medication administration records, and chart reviews. All inpatients should benefit from the identification and guidance of methods aimed at reducing drug-related harm. Additionally, the triggers methodology appears to be more reliable than the non-triggered chart review and the conventional ways of occurrence reports (Cullen DJ et al., 1997; Suresh G et al., 2004). The reasoning underlying the ADE's causality assessment is reflected in the development of the trigger. They could view comparable triggers from the literature on the right side of the screen as the clinician explained the reasons and effects. Triggers may be developed in the future to use comprehensive note data to identify a greater variety of AEs. (Rajput, D. S., 2024). We have looked at nearly 1571 triggers. We discovered that the trigger tool may be effectively and reliably used to characterize the breadth and depth of the ADEs found in various inpatient organizations by using teams of two medical professionals. The Pediatric and Medicine ward had the highest number of adverse drug reactions (ADRs), which were easily identified by looking at nursing notes and speaking with the resident physicians and nurses. Hu, X. (2024) This could be very helpful for future trigger tool standardization for ADE detection. In order to enable the quick identification of the ADE, we focused our efforts on creating a collaborative pharmacovigilance tool. Although the current study demonstrated the value of triggers for the early identification of adverse drug reactions, further investigation is required to determine how these tools might be used to avoid ADRs in various hospital settings. Therefore, the team focused their efforts on developing a measurement instrument that was easy to understand and reasonably easy to teach. The altered instrument had to be adaptable enough to be utilized in a variety of healthcare settings, such as academic medical centers and community hospitals. Since there were no standards available to compare our study against, we did not utilize any in this one. Establishing a baseline rate of ADEs and monitoring them over time requires adequate precision, repeatability, and consistency. The current study's flaw was that we didn't follow it for the outpatient. To identify the triggers, more study is required to track the ADE in the outpatient department.

5. CONCLUSION

The key components of pharmacological therapy are prescription patterns and medication safety monitoring. Even though educational interventional improvement in intensive event monitoring was found to be effective in increasing the quality and quantity of the ADR reporting, health care professionals are not good enough at reporting ADRs, and the authorities are not good enough at holding doctors to their doctors. This approach can be used by the hospital to report ADRs with more success. Consumer data can be helpful in identifying fresh facts on drug safety monitoring. Monitoring drug safety based on laboratory results is highly helpful in identifying adverse events. The most effective technique for early adverse event detection and prevention in all situations in intensive care units (ICUs) and other hospital units was determined to be the trigger tool method. Monitoring total drug volumes and more complex evaluations utilizing disease- or patient-specific quality indicators are both necessary for a proper assessment of prescribing quality. Prescribers will find the medication usage 90% technique more credible and helpful if it incorporates qualitative elements into commonly available aggregate data. 90% drug use was shown to be a useful metric for evaluating the general caliber of prescriptions.

REFERENCES

[1] LaRochelle JM, Smith KP, Benavides S, Bobo K, Chung AM, Farrington E, Kennedy A, Knoppert D, Lee B, Manasco KB, Pettit R. Evidence demonstrating the pharmacist's direct impact on clinical outcomes in pediatric patients: An opinion of the pediatrics practice and research network of the American College of Clinical Pharmacy. Journal of the American College of Clinical Pharmacy. 2020 Jun;3(4):786-92.

[2] Aniemeke E, Crowther B, Younts S, Hughes D, Franco-Martinez C. Clinical pharmacy discharge counseling service and the impact on readmission rates in high-risk patients. Hospital pharmacy. 2017 May;52(5):348-52.

[3] Gradwohl C, Engstler G, Anditsch M, Pichler H, Stemer G. The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology. Children. 2022 Mar 31;9(4):479.

[4] King PK, Burkhardt C, Rafferty A, Wooster J, Walkerly A, Thurber K, Took R, Masterson J, St. Peter WL, Furuno JP, Williams E. Quality measures of clinical pharmacy services during transitions of care. Journal of the American College of Clinical Pharmacy. 2021 Jul;4(7):883-907.

[5] Sathish Naik H, Padmamma S. Availability of E-Resources and ICT Infrastructure in Medical College Libraries of Deemed Universities in Karnataka. Indian Journal of Information Sources and Services. 2019;9(1):139-146.

[6] Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, Buck TC, Pottegård A, Hansen MR, Hallas J. Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: a randomized clinical trial. JAMA internal medicine. 2018 Mar 1;178(3):375-82.

[7] Seidgar M, Hafezieh M, Nekoueifard A, Ghara K, Alizadeh Osalou Z, Mohebbi F, Rezaei MM. The effect of mechanization on the growth and nutritional indicators of dual-purpose rainbow trout culture farms in Markazi Province, Iran. International Journal of Aquatic Research and Environmental Studies. 2024 May 10;4(1):13-22.

[8] Renaudin P, Boyer L, Esteve MA, Bertault-Peres P, Auquier P, Honore S. Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis. British journal of clinical pharmacology. 2016 Dec;82(6):1660-73.

[9] Parthasarathy S, Lakshminarayanan AR, Khan AA, Sathick KJ. CSA-forecaster: Stacked model for forecasting child sexual abuse. Journal of Internet Services and Information Security. 2024;14(1):219-41.

[10] Renaudin P, Baumstarck K, Daumas A, Esteve MA, Gayet S, Auquier P, Tsimaratos M, Villani P, Honore S. Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial. Trials. 2017 Dec;18:1-8.

[11] Joshi P, Singh K. Strength of Materials: Analysis and Design of Mechanical Components. Association Journal of Interdisciplinary Technics in Engineering Mechanics. 2024 Dec 26;2(4):1-5. Canales HB, Reyes EM, Vásquez AP, Correa SR, Vela CA, Ramírez JA, Ruiz ER, Flores-Tananta CA. Financial Model Construction and Identification of Abnormal Activities in Mobile Networks for e-commerce Platform Using Machine Learning Algorithm.

[12] Sharma R, Maurya S. A Sustainable Digital Transformation and Management of Small and Medium Enterprises through Green Enterprise Architecture. Global Perspectives in Management. 2024;2(1):33-43.

[13] Koohpaei A, Khandan M. Survey Mental Health Status and Related Factors among Food Industry Workers in a Province of Iran. International Academic Journal of Social Sciences. 2015;2(6):1-9.

[14] Khyade VB, Wanve HV. Statistics as Efficient Tool of Analysis in the Biomedical Research. International Academic Journal of Science and Engineering. 2018;5(1):73–84.

[15] dos Santos Alcântara T, Carvalho GA, Sanchez JM, Ramos SF, Cunha LC, de Castro Araújo-Neto F, Valença-Feitosa F, Silvestre CC, de Lyra Junior DP. Quality indicators of hospitalized children influenced by clinical pharmacist services: a systematic review. Research in Social and Administrative Pharmacy. 2023 Oct 1;19(10):1315-30.

[16] Rajput DS. Investigating the Role of Genetic Variants in Drug-Induced Liver Injury. Clinical Journal for Medicine, Health and Pharmacy. 2024 Mar 29;2(1):30-9.

[17] Wan Q, Hu X. Legal Framework for Security of Organ Transplant Information in the Digital Age with Biotechnology. Natural and Engineering Sciences. 2024 Sep 1;9(2):73-93.